NMRA-511 Phase 1b Study Results - NMRA-511 Phase 1b study is for Alzheimer's Disease (AD) Agitation [2] - The company is focused on redefining neuroscience drug development [4] - Alzheimer's disease affects approximately 7 million U S adults in 2024, and this number is expected to increase to 13 million by 2050 [12] - Over 70% of people with Alzheimer's Disease experience agitation at some point [12] - NMRA-511 demonstrated a 15 7-point reduction in CMAI total score at Week 8 [47] NMRA-511 Clinical Trial and Safety - In the NMRA-511 Phase 1b study, 40 participants were in the NMRA-511 group and 40 in the placebo group [45] - 45% of the NMRA-511 group were male, compared to 37 5% in the placebo group [45] - 67 5% of the NMRA-511 group were White, compared to 75% in the placebo group [45] - Protocol-defined medication non-adherence was observed in 17 5% of the NMRA-511 group [45] - The company plans to initiate a multiple ascending dose extension in 2026 to enable higher dosing [61]

Pipeline Highlights - Neumora is advancing a broad neuroscience pipeline targeting prevalent diseases with novel mechanisms [18] - Multiple catalysts are expected over the next 12 months, including data readouts for Navacaprant and NMRA-511, and advancing NMRA-861 and NMRA-898 to the clinic [20, 21] NMRA-215 (Obesity) - By 2030, 1.13 billion people worldwide are projected to be living with obesity, driving a significant market for obesity treatments estimated at $130-$170 billion [26] - NMRA-215 demonstrated best-in-class monotherapy weight loss of up to 19% in preclinical studies [29, 47] - Combination therapy with NMRA-215 and semaglutide resulted in up to 26% weight loss [30, 50] - NMRA-215 monotherapy matches semaglutide weight loss, while preserving lean mass [56] NMRA-511 (Alzheimer's Disease Agitation) - Approximately 7 million U S adults have Alzheimer's Disease, and this number is expected to increase to 13 million by 2050 [19, 72] - Over 70% of people with Alzheimer's Disease experience agitation at some point [72] - NMRA-511 Phase 1b study data is anticipated around the end of 2025 [66, 142] M4 PAM Franchise (Schizophrenia) - An estimated 3 million patients in the U S have schizophrenia [19, 100] - Neumora has multiple chemically distinct, highly selective M4 muscarinic receptor PAMs, including NMRA-861 and NMRA-898 [99] - NMRA-861 and -898 potentially have more potency than emraclidine across multiple assays [116]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Neumora Therapeutics, Inc. related to misrepresentation in clinical trial data [1][2]. Group 1: Legal Investigation - Kuehn Law is looking into whether Neumora Therapeutics' insiders misrepresented or failed to disclose critical information regarding the company's Phase Three Program [2]. - The investigation centers on amendments made to BlackThorn's original Phase Two Trial inclusion criteria, which were altered to include patients with moderate to severe Major Depressive Disorder (MDD) [2]. - The Phase Two Trials reportedly lacked sufficient data, particularly concerning patient population size and gender ratio, which raises concerns about the predictive accuracy for the KOASTAL-1 study results [2]. Group 2: Shareholder Actions - Shareholders who purchased NMRA shares before September 15, 2023, are encouraged to contact Kuehn Law to discuss their rights and potential involvement in the investigation [3]. - Kuehn Law offers to cover all case costs for investor clients, emphasizing the importance of timely action for shareholders [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Neumora Therapeutics, Inc. common stock about the April 7, 2025 deadline to become a lead plaintiff in a securities class action related to the company's September 2023 IPO [1]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2025, to serve as lead plaintiff, representing other class members [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement against a Chinese company and being ranked highly by ISS Securities Class Action Services [4]. Group 3: Case Specifics - The lawsuit alleges that Neumora's Offering Documents contained false or misleading statements regarding the Phase Three Program and the adequacy of data from Phase Two Trials, which misled investors about the company's prospects [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [2][3]. Group 1: Allegations - The lawsuit claims that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [2]. - It is alleged that the company added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The complaint also states that the Phase Two Trials lacked adequate data, particularly concerning the patient population size and the male-to-female ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 2: Class Action Details - The class period for the lawsuit commenced on or about September 15, 2023, and shareholders are encouraged to register by April 7, 2025, to participate [1][3]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals or entities that acquired Neumora common stock based on the Offering Documents [2]. Case Details - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and the Phase Two trials of its flagship therapeutic candidate, Navacaprant. Specifically, it claims that: - Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to demonstrate statistically significant improvement [3]. - A prespecified analysis was added to the Phase Two statistical analysis plan focusing on patients with moderate to severe MDD [3]. - The Phase Two Trials lacked adequate data, particularly concerning patient population size and gender ratio, which hindered accurate predictions for the KOASTAL-1 study results [3]. Next Steps - Investors who suffered losses in Neumora Therapeutics, Inc. during the relevant timeframe have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements and failure to disclose critical information regarding its clinical trials, particularly related to its flagship therapeutic candidate, Navacaprant [3]. Group 1: Legal Action and Investor Information - The Portnoy Law Firm is representing investors who purchased Neumora common stock starting from September 15, 2023, and they have until April 7, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims to recover losses [2]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora altered the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [3]. - The company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD, which raises concerns about the validity of the trial results [3]. - There were significant deficiencies in the Phase Two trials, particularly regarding patient population size and the male-to-female ratio, which complicates the prediction of outcomes for the KOASTAL-1 study [3].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals or entities who purchased Neumora common stock during the class period starting on or about September 15, 2023 [3]. - The deadline for shareholders to register for the class action is April 7, 2025, and they are encouraged to register to monitor the case's progress [5]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [4]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [4]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [6]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements by companies [6].

Core Viewpoint - Rosen Law Firm is urging investors of Neumora Therapeutics, Inc. to secure legal counsel before the April 7, 2025 deadline for a securities class action related to the company's IPO in September 2023 [1][2]. Group 1: Legal Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [5].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2] - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the predictability of the KOASTAL-1 study results [2] Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]